Compare Dover Corp (DOV) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dover Corp vs Twist Bioscience Corp — how do they compare? Dover Corp trades at $207.85 (market cap $28.07B), while Twist Bioscience Corp trades at $121.73 (market cap $7.72B). The key difference: Dover Corp is far larger — about 3.6× Twist Bioscience Corp's market cap, and Dover Corp pays a 1.01% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| DOV | TWST | |
|---|---|---|
Market Cap | $28.07B | $7.72B |
Sector | Industrials | Health |
52-Week High | $233.31 | $124.88 |
52-Week Low | $161.16 | $24.16 |
Enterprise Value | $29.58B | $7.65B |
Dividend Yield | 1.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dover Corporation (DOV) trades at $210.1, down 0.49% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported strong Q2 2026 results with EPS of $2.74, exceeding expectations, and raised full-year guidance. Recent dividend increases and strategic acquisitions, such as Cloeren, highlight management's confidence in growth. Valuation ratios like P/E of 25.21 and ROE of 14.98% reflect solid profitability, though the stock faces resistance near $212.
The outlook for DOV is positive, driven by robust fundamentals and analyst consensus favoring a buy rating with a $232.33 price target. Risks include market volatility and execution challenges from acquisitions, but diversified end-market exposure and margin expansion support upside potential for investors seeking steady income and growth.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dover Corp
Dover is a diversified industrial manufacturing company with products and services that include digital printing for fast-moving consuming goods, marking and coding for the food and beverage industry, loaders for the waste collection industry, pumps for the transport of fluids, including petroleum and natural gas, and commercial refrigerators used in groceries and convenience stores. Most of the business operates in the United States. After the spinoff of Apergy, the company operates through five segments: engineered systems, clean energy and fueling solutions, imaging and identification, pumps and process solutions, and climate and sustainability technologies equipment.
Read more on DOV →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
